1. Home
  2. FDMT

as 11-20-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Founded: 2013 Country:
United States
United States
Employees: N/A City: EMERYVILLE
Market Cap: 420.7M IPO Year: 2020
Target Price: $46.75 AVG Volume (30 days): 759.8K
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.83 EPS Growth: N/A
52 Week Low/High: $7.32 - $36.25 Next Earning Date: 11-13-2024
Revenue: $17,000 Revenue Growth: -99.92%
Revenue Growth (this year): -70.79% Revenue Growth (next year): 57.85%

FDMT Daily Stock ML Predictions

Stock Insider Trading Activity of 4D Molecular Therapeutics Inc. (FDMT)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Bizily Scott FDMT Chief Legal Officer Sep 16 '24 Sell $16.33 500 $8,165.00 6,781

Share on Social Networks: